New pain pill enters first human safety tests

NCT ID NCT07618247

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial will test the safety and tolerability of a new experimental drug called IG001119 in 64 healthy volunteers. Participants will receive either the drug or a placebo tablet. The study aims to understand how the drug behaves in the body and identify any side effects, but it does not test whether the drug actually relieves pain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
IG001119 (oral tablet)
What this could lead to
If safe and well-tolerated, this could pave the way for a new pain treatment option.
What could go wrong
This is a very early Phase 1 trial in healthy people, not patients with pain. It only tests safety and dosing, not whether the drug actually works for pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CMAX

    Adelaide, South Australia, Australia, 5000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.